At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 76 enrolled
Drug / intervention
Fostamatinib 150 mg +2 moredrug
Likely dose
Fostamatinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
In Brief
A Phase 2 clinical trial evaluating Fostamatinib 150 mg, Fostamatinib 100 mg, and 1 other intervention for IGA Nephropathy. Completed, enrolled 76 participants across 20 sites in 6 countries.
Detailed Summary
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIGA Nephropathy
CountriesAustria, Germany, Hong Kong, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartOct 2014
Primary CompletionMar 2018
Study CompletionNov 2018
TodayJul 2026
First PostedApr 14, 2014
Enrollment StartOct 1, 2014
Primary CompletionMar 23, 2018
Study CompletionNov 12, 2018
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 12.2 years ago
Interventions
Fostamatinib 150 mgdrug
Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mgdrug
Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Placebodrug
Placebo tablet twice daily by mouth, over the course of 24 weeks